Improving early diagnosis of dementia in primary care
The Swedish BioFINDER - Primary Care Study
This study is trying to find better ways to diagnose Alzheimer's and other memory problems early in people visiting their primary care doctors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1200 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Skane University Hospital Academic / other |
| Locations | 1 site (Malmö) |
| Trial ID | NCT06120361 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance the diagnostic accuracy of Alzheimer's disease and cognitive impairment in primary care settings. It focuses on recruiting diverse patients with subjective cognitive decline, mild cognitive impairment, and mild dementia. The study will evaluate cognitive tests, blood-based biomarkers, and brain imaging methods to facilitate early diagnosis and improve patient management. By comparing traditional and novel cognitive screening tools, the study seeks to identify the most effective methods for early detection in primary care.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 40 and older experiencing cognitive symptoms such as memory complaints or other cognitive difficulties.
Not a fit: Patients who have already been diagnosed with dementia or have cognitive impairment due to acute conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of dementia, improving patient care and treatment outcomes.
How similar studies have performed: Other studies have shown promise in using blood biomarkers and cognitive tests for early diagnosis of dementia, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The patient seeks medical help because of cognitive symptoms experienced by the patient and/or informant OR The general practitioner suspects a progressive neurodegenerative disorder including, but not limited to, Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration or subcortical vascular cognitive impairment. 2. The main symptom is usually memory complaints, but could also be executive, visuo-spatial, language, or attention complaints. 3. Age ≥40 years 4. Subjective cognitive decline, mild cognitive impairment or mild dementia Exclusion Criteria: 1. Already diagnosed dementia 2. Significant unstable systemic illness or organ failure that makes it difficult to participate. 3. Current significant alcohol or substance misuse. 4. Refusing investigation at the Memory clinic 5. Cognitive impairment with acute onset due to stroke 6. The cognitive impairment can with certainty be explained by another condition or disease such as significant anemia, infection, severe sleep deprivation, psychotic disorder, moderate-severe depression, alcohol abuse etc.
Where this trial is running
Malmö
- Primary care centers in Region Skåne — Malmö, Sweden (Recruiting)
Study contacts
- Principal investigator: Erik Stomrud, MD, PhD — Skane University Hospital and Lund University
- Study coordinator: Sebastian Palmqvist, MD, PhD
- Email: Sebastian.Palmqvist@med.lu.se
- Phone: +46-40-331000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.